POSSIBILITIES OF METHORMINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: TEST OF TIME


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Type 2 diabetes mellitus (DM2) is an actual modern medical and social problem. The review article discusses the pathogenesis of the disease. The important role of insulin resistance as a key link in the development of DM2 is emphasized. Details of the mechanism of action of metformin, its glycemic and extra-glycemic effects, the place of the drug in modern diabetes therapy are considered.

全文:

受限制的访问

作者简介

E. Biryukova

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Email: lena@obsudim.ru
MD, Prof., MSMSU Moscow, Russia

I. Solovyeva

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Moscow, Russia

N. Platonova

Scientific Medical Research Center of Endocrinology

Moscow, Russia

参考

  1. IDF http://www.diabetesatlas.org/
  2. Дедов И.И., Шестакова М.В. Сахарный диабет. 2007;3:55-7.
  3. Kooy A., de Jager J., Lehert P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern Med. 2009;169:616-25.
  4. Hemmingsen B., Lund S., Wetterslev J., Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur. J. Endocrinol. 2009;161:1-9.
  5. Meier M., Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag. 2009;5:859-71.
  6. Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med. 1996;334:574-79.
  7. Rotella C.M., Monami M., Mannucci E. Metformin beyond diabetes: new life for an old drug. Curr. Diabet. Rev. 2006;2:307-15.
  8. Mann-Pehalver J.J., Martln-Timon I., Sevillano-Collantes C., Del Cahizo-Gomez F.J. Update on the treatment of type 2 diabetes mellitus. World J. Diabet. 2016;7(17):354-95. Doi: 10.4239/ wjd.v7.i17.354.
  9. Kinaan M., Ding H., Triggle C.R. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Med. Princ. Pract. 2015;24:401-15. doi: 10.1159/000381643.
  10. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin. An Update. Ann. Intern. Med. 2002;137:25-33.
  11. Godarzi M.O., Brier-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabet. Obes. Metab. 2005;5:654-65.
  12. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
  13. Rojas L.B.A., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes Diabet. Metabolic. Syndrome. 2013;5:6. Doi. org/10.1186/1758-5996-5-6.
  14. Coutinho M., Gerstein H., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events, a metaregression analysis of published data from 20 studies of 95783 individuals followed for 12,4 years. Diabet. Care. 1999;22:233-40.
  15. Coughlan K.A., Valentine R.J., Ruderman N.B., et al. AMPK activation: a therapeutic target for type 2 diabetes? Diabet. Metab. Syndr. Obes. 2014;7:241-53.
  16. Foretz M., He'brard S., Leclerc J., Zarrinpashneh E., Soty M., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010;120:2355-69.
  17. Markowicz-Piasecka M., Huttune M.K., Lukasz M., et al. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr. Pharm. Des. 2017;23:1-19.
  18. Pryor R., Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem. J. 2015;471(3):307-22.
  19. Shinmura K., Negoro T., Shimizu S., et al. Metformin Modulates GLP-1- and GIP-Mediated Intracellular Signaling under Normoglycemic Conditions. Open J. Endocr. Metab. Dis. 2013;3:263-70.
  20. McCreight L.J., Bailey C.J., Pearson E.R. Metformin and the gastrointestinal tract. Diabet. 2016;59(3):426-35.
  21. Lien F., Berthier A., Bouchaert E., et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 2014;124:1037-51.
  22. Schwartz S.S., Epstein S., Corkey B.E., et al. The time is right for a new classification system for diabetes: rationale and implications of the ß-cell-centric classification schema. Diabet. Care. 2016;39:179-86.
  23. Мкртумян А.М., Бирюкова Е.В. Болезни сердца и сосудов. 2007;2:31-5.
  24. Berkowitz S.A., Krumme A.A., Avorn J. Initial choice of oral glucose-lowering medication for diabetes mellitus a patient-centered comparative effectiveness study. JAMA. Intern. Med. 2014;174(12):1955-62. Doi:10.1001/ jamainternmed.2014.5294.
  25. Malin S.K., Kashyap S.R Effects of metformin on weight loss: potential mechanisms. Current Opinion in Endocrinology, Diabet. Obes. 2014;21(5):323-29.
  26. Kim H.-J., Jin B.Y., Oh M.-J., Shin K.-H., ChoiS.-H., Kim D.-H. The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. Physiol. Behavior. 2016;154:184-19. Doi.org/10.1016/j.physbeh.2015.11.028.
  27. Malin S.K., Sangeeta R.K. Effects of metformin on weight loss: potential mechanisms. Current Opinion in Endocrinology, Diabet. Obes. 2014;21(5):323-9. Doi: 10.1097/ MED.0000000000000095.
  28. Chau-Van C., Gamba M., Salvi R., et al. Metformin Inhibits Adenosine 5'-Monophosphate-Activated Kinase Activation and Prevents Increases in Neuropeptide Y Expression in Cultured Hypothalamic Neurons. Endocrinol. 2007;148(2):507-11.
  29. Li Y., Xu S., Mihaylova M.M., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell. Metab. 2011;13:376-88.
  30. Mamputu J.C., Wiernsperger N.F., Renier G.A. Antiatherogenic properties of metformin: the experimental evidence. Diabet. Metab. 2003;29:6S71-76.
  31. Ouslimani N., Mahrouf M., Peynet J., et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism. 2007;56(3):308-13.
  32. Chakraborty A., Chowdhury S., Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabet. Res. Clin. Pr. 2011;93:56-62.
  33. Johnson J.A., Majumdar S.R., Simpson S.H: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabet. Care. 2002;25:2244-48.
  34. Kao J., Tobis J., Mc Clelland R.L. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am. J. Cardiol. 2004;93:1347-50. doi: 10.1016/j.amjcard.2004.02.028.
  35. Holden S.E., Jenkins-Jones S., Currie C.J. Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS One. 2016;6;11(5):e0153594. Doi: 10.1371/ journal.pone.0153594.
  36. Lee H., Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl. Environ Microbiol. 2014;80:5935-43.
  37. Кожевников А.А., Раскина К.В., Мартынова Е.Ю. Тяхт А. Участие кишечной микробиоты в процессах метаболизма, старения и перспективы применения имеющихся данных в реальной клинической практике. РМЖ. «Медицинское обозрение» 2017;2:98-105.
  38. Decensi A., et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev. Res. (Phila). 2010;3(11):1451-61.
  39. Coyle C., Cafferty F.H., Vale C., et al. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. 2016;27(12):2184-95.
  40. Kasznicki J., Sliwinska A., Drzewoski J. Metformin in cancer prevention and therapy. Ann. Transl. Med. 2014;2(6):57. doi: 10.3978/j.issn.2305-5839.2014.06.01.
  41. Topcu S., Tok D., Caliskan M. Metformin therapy improves coronary microvascular function in patient with polycystic ovary syndrom and insulin resistence. Clin. Endocrinol. (Oxf). 2006;65(1):75-80.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##